Second-line treatment in invasive mould infections

Mycoses

Volumn 49, Issue SUPPL. 1, 2006, Pages 23-26

  Karthaus, Meinolf ^a   Cornely, Oliver A ^b  

^a EVANGELISCHES KRANKENHAUS   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Antifungal; Antigen assay; Aspergillosis; Azole; Candida; Echinocandin; Infection; Invasive fungal infection

Indexed keywords

AMPHOTERICIN B; CALCIUM CHANNEL BLOCKING AGENT; CASPOFUNGIN; CYCLOSPORIN A; CYTOCHROME P450 3A4; FLUCONAZOLE; ITRACONAZOLE; MACROLIDE; MICAFUNGIN; POSACONAZOLE; RIFABUTIN; RIFAMPICIN; VORICONAZOLE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ASPERGILLOSIS; BLOOD LEVEL; CLINICAL TRIAL; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; GASTROINTESTINAL SYMPTOM; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; LIVER FUNCTION TEST; LUNG ASPERGILLOSIS; MORTALITY; MUCORMYCOSIS; MYCOSIS; PREVALENCE; PRIORITY JOURNAL; RASH; REVIEW; UNSPECIFIED SIDE EFFECT; VISUAL DISORDER;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; HUMANS; MYCOSES; SALVAGE THERAPY; TREATMENT OUTCOME; TRIAZOLES; ZYGOMYCOSIS;

CANDIDA;

EID: 33748572932     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2006.01298.x     Document Type: Review

References (8)

1. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-15.
2. Cornely OA, Maeertens J, Bresnik M, Herbrecht R. Liposomal AmB (L-AmB) as initial therapy of invasive filamentous fungal infections (IFI): a randomized, prospective trial of a high loading regimen vs. standard dosing (AmBiload Trial). 47th Annual Meeting of ASH. 2005: A-3222.
3. Maertens J, Raad I, Sable CA et al. Multicenter, noncomparative study to evaluate safety and efficacy of caspofungin (CAS) in adults with invasive aspergillosis (IA) refractory (R) or intolerant (I) to amphotericin B (AMB), AMB lipid formulations (Lipid AMB), or azoles. 40th ICAAC, Toronto, 2000: (Abstract 1103: 371), CID 2004.
4. Denning DW, Marr KA, Lau WM, Facklam DP et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents for the treatment of acute invasive apergillosis. J Infect. 2006: May 5: [Epub ahead of print].
5. Walsh TJ, Patterson T, Langston A et al. Posaconazole for treatment of invasive aspergillosis in patients who are refractory to or intolerant of conventional therapy: an externally controlled blinded trial. Proceedings 45th ASH. 2003: (Abstract 682).
6. Alexander B, Perfect J, Daly J et al. Posaconazole (POS) as salvage therapy in patients with invasive fungal infections (IFIs) following solid-organ transplant (SOT). Program and Abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, 2005: December 16-19 (Abstract M-959).
7. Kontoyiannis DP, Hare R, Solomon H et al. Posaconazole is highly effective as a second-line agent in zygomycosis: summary of 91 cases. Program and Abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, 2005: December 16-19 (Abstract M-974).
8. van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006: 42: e61-e65.